Impact of innovation in oncology: more questions than answers

被引:3
|
作者
Fasola, Gianpiero [1 ,2 ]
Barducci, Maria Carla [3 ]
Beretta, Giordano [4 ,5 ]
机构
[1] Univ Hosp S Maria Misericordia, Dept Oncol, Udine, Italy
[2] Coll Italiano Primari Oncol Med Osped, Palermo, Italy
[3] SDA Bocconi Univ, MIMS, Lombardia, Italy
[4] Humanitas Gavazzeni, Dept Oncol, Lombardia, Italy
[5] Assoc Italiana Oncol Med, Palermo, Italy
来源
TUMORI JOURNAL | 2021年 / 107卷 / 06期
关键词
Innovation; prevalence; knowledge; health care; AMERICAN SOCIETY; CANCER CARE;
D O I
10.1177/03008916211027646
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Oncology is going through the fastest innovation period in the history of medicine and a growing number of patients improve or experience increased chances of survival. The declining death rate, starting from 1991, resulted in 2.9 million deaths avoided in the United States so far. A growing prevalence of patients is observed in all Western countries. New cancer drug approvals between 2000 and 2016, linked to other diagnostic, surgical, and health care improvements, were significantly associated with death reduction for the most common cancers. Alongside many positive aspects, other effects of innovations in oncology also deserve attention, especially challenges associated with the substantial increase of knowledge volume, the sharp growth of prevalence, and a concomitant or consequent increase in clinical, social, and organizational complexity. We analyse some of the consequences of oncology innovation on healthcare systems and professionals and present some suggestions on how these could be addressed by healthcare systems.
引用
收藏
页码:478 / 482
页数:5
相关论文
共 50 条